A leading global animal health organisation has contracted Abingdon Health since 2019 for end-to-end CDMO solutions. The project focused on optimising, transferring, and scaling up manufacturing processes, delivering a high-quality, market-ready lateral flow diagnostic device for animal care. Following successful delivery, Abingdon Health was retained for routine manufacturing spanning multi-deal agreements which continue to date.
Challenges
The customer faced two significant challenges linked to manufacturing of their animal health lateral flow diagnostic device.
- A contractual KPI of 98% of orders being delivered On Time In Full (OTIF) was not being consistently met, impacting supply chain reliability; and
- An important chemical component within the test required replacement due to evolving regulatory requirements, necessitating a solution that would maintain the test's critical performance and shelf-life stability.
Solution
To improve OTIF performance, Abingdon’s worked closely and collaboratively with the customer to gain a deep understanding of their specific KPI measurement methodology. Using this insight and leveraging its world class manufacturing expertise & facilities, Abingdon updated and refined their internal production plans and operational approach, ensuring consistent adherence to the stringent delivery metrics.
Simultaneously, Abingdon’s scientific team identified and evaluated alternative surfactants to replace the chemical component which required replacement. Modified test devices were then manufactured and subsequently entered into rigorous stability studies. Throughout this process, the customer was kept updated ensuring transparency at critical points and informed decision-making.
Results & Impact
Following the OTIF review in 2021, and with the improved understanding of the customer’s KPI metric, Abingdon greatly improved OTIF rates in the first 12 months, and since 2023 has achieved a 100% performance against the challenging OTIF metric, ensuring reliable supply for our client's global operations. Abingdon’s R&D team also identified a robust alternative surfactant, future-proofing the product's regulatory compliance and securing its continued market availability. This achievement underscores our ability to not only deliver operational excellence, but also to provide innovative scientific solutions that directly impact product longevity and market access.
"We renewed our contract manufacturing agreement with Abingdon Health once again in 2023, because we trust Abingdon to deliver quality products with care, and their proven CDMO track record in lateral flow technologies minimises our risk. They consistently deliver against key metrics, demonstrating exceptional speed and flexibility in manufacturing IVD diagnostics at scale. Their efficient project delivery through quality-assured scientific precision is outstanding. Based on their exceptional account delivery and deep lateral flow expertise, we have also commissioned Abingdon Health to deliver several critical device development projects that ensure the continuity and future success of our product portfolio."
Why did you choose Abingdon Health?
Choosing Abingdon Health is a strategic decision for any diagnostics company. Their proven CDMO expertise in lateral flow isn't just about manufacturing; it's about building trust and truly understanding your needs. They expertly balance scale, speed, and flexibility with unwavering quality and compliance, ensuring efficient project delivery and enabling you to minimise risk and maximise potential. Their scientific precision, from R&D to routine supply, makes them an invaluable partner for both innovation and reliable external supply.
